Stern Z, Zylber-Katz E, Levy M
Int J Clin Pharmacol Ther Toxicol. 1984 Apr;22(4):198-203.
Nifedipine, a "calcium channel blocker", is increasingly employed in the treatment of angina pectoris. Large interindividual differences have been observed in the effective dosage of the drug. Many of the reported alleged adverse reactions to nifedipine are linked to its primary pharmacologic action - vasodilatation. Therefore in 15 patients with angina pectoris we studied the relation between nifedipine concentration in the plasma and its clinical effects. Although in individual patients an increase in daily dose from 30 to 50 mg was followed by increased plasma levels and cessation of anginal attacks, no "therapeutic plasma range" could be delineated. Similarly, although some patients developed a headache when relatively high levels were measured, these levels still overlapped with those found in asymptomatic patients.
硝苯地平,一种“钙通道阻滞剂”,越来越多地用于治疗心绞痛。已观察到该药物有效剂量存在较大个体差异。许多报道的所谓硝苯地平不良反应与其主要药理作用——血管舒张有关。因此,我们对15例心绞痛患者研究了血浆中硝苯地平浓度与其临床疗效之间的关系。尽管个别患者每日剂量从30毫克增加到50毫克后血浆水平升高且心绞痛发作停止,但无法划定“治疗性血浆范围”。同样,尽管一些患者在测量到相对较高水平时出现头痛,但这些水平仍与无症状患者的水平重叠。